APUS vs TXT · $2.4M cap vs P/E 19, rev $7.52B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Textron Inc (TXT) is a aerospace & defense company listed on US.
APUS does not have a complete income-statement cache yet.
Latest reported TXT revenue for 2026-07-04 was $7.52B. Net income was $468.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
APUS currently screens at market cap $2.4M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the APUS and TXT stock pages for the full models.
Not investment advice.